GILD
Gilead Sciences, Inc. NASDAQ Listed Jan 22, 1992$134.12
After hrs
$131.77
+0.33%
Mkt Cap $166.5B
52w Low $95.30
62.6% of range
52w High $157.29
50d MA $139.40
200d MA $127.18
P/E (TTM)
19.2x
EV/EBITDA
15.7x
P/B
7.2x
Debt/Equity
1.1x
ROE
37.5%
P/FCF
16.1x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$139.40
200d MA
$127.18
Avg Volume
6.6M
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
333 Lakeside Drive · Foster City, CA 94404 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | 1.91 | 2.03 | +6.3% | 134.06 | -3.0% | -2.0% | — | — | — | — | — |
| Feb 10, 2026 | AMC | 1.81 | 1.86 | +2.8% | 147.23 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% | — |
| Oct 30, 2025 | AMC | 2.13 | 2.47 | +16.0% | 118.44 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% | — |
| Aug 7, 2025 | AMC | 1.96 | 2.01 | +2.6% | 110.28 | +4.5% | +8.3% | +9.2% | +8.8% | +8.9% | +7.9% | — |
| Apr 24, 2025 | AMC | 1.78 | 1.81 | +1.7% | 106.15 | -3.3% | -2.8% | +0.2% | -1.8% | +0.4% | -2.7% | — |
| Feb 11, 2025 | AMC | 1.74 | 1.90 | +9.2% | 96.14 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% | — |
| Nov 6, 2024 | AMC | 1.53 | 2.02 | +32.0% | 91.69 | +2.5% | +6.8% | +5.3% | +5.8% | +2.9% | +1.0% | — |
| Aug 8, 2024 | AMC | 1.61 | 2.01 | +24.8% | 75.59 | -0.9% | -2.6% | -3.4% | -2.1% | -1.9% | -1.7% | — |
| Apr 25, 2024 | AMC | -1.49 | -1.32 | +11.4% | 65.27 | +0.4% | +0.2% | +1.0% | -0.1% | +0.4% | +0.1% | — |
| Feb 6, 2024 | AMC | 1.76 | 1.72 | -2.3% | 77.72 | -1.9% | -4.2% | -5.0% | -5.2% | -4.2% | -5.4% | — |
| Nov 7, 2023 | AMC | 1.91 | 2.29 | +19.9% | 80.61 | -3.9% | -3.4% | -7.0% | -5.8% | -7.0% | -7.3% | — |
| Aug 3, 2023 | AMC | 1.60 | 1.34 | -16.2% | 75.53 | +2.4% | +4.2% | +6.8% | +6.0% | +6.1% | +5.9% | — |
| Apr 27, 2023 | AMC | 1.63 | 1.37 | -16.0% | 83.55 | -1.2% | -1.6% | -2.5% | -3.7% | -4.9% | -6.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | Citigroup | Maintains | Buy → Buy | — | $138.99 | $137.99 | -0.7% | +0.0% | +1.1% | +0.6% | -0.3% | -1.0% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $142.09 | $142.38 | +0.2% | -2.2% | -2.2% | -1.2% | -1.6% | -2.5% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $151.40 | $148.93 | -1.6% | -1.0% | -2.5% | -2.8% | -5.0% | -1.6% |
| Feb 11 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Needham | Maintains | Buy → Buy | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Truist | Maintains | Buy → Buy | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Feb 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $147.23 | $148.90 | +1.1% | +5.8% | +3.1% | +5.3% | +5.5% | +3.7% |
| Jan 27 | Citigroup | Maintains | Buy → Buy | — | $137.78 | $137.54 | -0.2% | +2.3% | +1.4% | +1.3% | +3.0% | +3.7% |
| Jan 27 | Truist | Maintains | Buy → Buy | — | $137.78 | $137.54 | -0.2% | +2.3% | +1.4% | +1.3% | +3.0% | +3.7% |
| Jan 26 | UBS | Maintains | Buy → Buy | — | $135.93 | $135.88 | -0.0% | +1.4% | +3.7% | +2.8% | +2.7% | +4.4% |
| Jan 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $122.60 | $122.59 | -0.0% | -0.7% | +1.2% | -1.1% | +1.9% | +1.3% |
| Jan 7 | Citigroup | Maintains | Buy → Buy | — | $121.36 | $122.34 | +0.8% | +2.5% | -0.6% | -0.2% | +1.0% | +0.3% |
| Dec 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $123.21 | $122.86 | -0.3% | -2.3% | -2.8% | -3.6% | -1.5% | -1.4% |
| Dec 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $119.36 | $119.49 | +0.1% | +1.7% | +3.2% | +0.9% | +0.4% | -0.5% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $123.40 | $123.75 | +0.3% | +1.5% | +1.3% | +0.6% | +3.1% | +3.8% |
| Nov 3 | Truist | Maintains | Buy → Buy | — | $119.79 | $119.82 | +0.0% | +1.9% | +2.7% | +2.3% | +3.0% | -0.8% |
| Oct 31 | JP Morgan | Maintains | Overweight → Overweight | — | $118.44 | $116.06 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $118.44 | $116.06 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% |
| Oct 31 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $118.44 | $116.06 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% |
| Oct 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $118.44 | $116.06 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% |
| Oct 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $118.44 | $116.06 | -2.0% | +1.1% | +3.0% | +3.9% | +3.5% | +4.2% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $121.46 | $121.75 | +0.2% | -0.6% | -0.4% | -0.8% | -2.9% | -2.4% |
| Oct 8 | Citigroup | Maintains | Buy → Buy | — | $116.78 | $117.11 | +0.3% | +1.3% | -0.0% | +0.3% | +1.2% | +1.5% |
| Sep 16 | JP Morgan | Maintains | Overweight → Overweight | — | $112.54 | $113.22 | +0.6% | -1.5% | -0.2% | +1.0% | +1.4% | -0.0% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $110.28 | $115.22 | +4.5% | +8.3% | +9.2% | +8.8% | +8.9% | +7.9% |
| Aug 8 | BMO Capital | Maintains | Outperform → Outperform | — | $110.28 | $115.22 | +4.5% | +8.3% | +9.2% | +8.8% | +8.9% | +7.9% |
| Aug 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $110.28 | $115.22 | +4.5% | +8.3% | +9.2% | +8.8% | +8.9% | +7.9% |
| Aug 8 | Truist | Upgrade | Hold → Buy | — | $110.28 | $115.22 | +4.5% | +8.3% | +9.2% | +8.8% | +8.9% | +7.9% |
| Jul 25 | Needham | Upgrade | Hold → Buy | — | $113.20 | $114.56 | +1.2% | +2.7% | -0.2% | +0.9% | +1.4% | -0.8% |
| May 21 | Needham | Maintains | Hold → Hold | — | $109.11 | $108.11 | -0.9% | -1.3% | -2.2% | -1.6% | -0.0% | -0.6% |
| May 5 | Mizuho | Maintains | Outperform → Outperform | — | $103.68 | $103.72 | +0.0% | -0.8% | -5.6% | -4.6% | -5.3% | -6.5% |
| Apr 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $106.15 | $102.68 | -3.3% | -2.8% | +0.2% | -1.8% | +0.4% | -2.7% |
| Apr 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $106.15 | $102.68 | -3.3% | -2.8% | +0.2% | -1.8% | +0.4% | -2.7% |
| Apr 25 | Needham | Maintains | Hold → Hold | — | $106.15 | $102.68 | -3.3% | -2.8% | +0.2% | -1.8% | +0.4% | -2.7% |
| Apr 17 | BMO Capital | Maintains | Outperform → Outperform | — | $104.88 | $104.74 | -0.1% | -0.3% | -0.5% | +0.6% | +1.4% | +1.2% |
| Mar 27 | JP Morgan | Maintains | Overweight → Overweight | — | $109.27 | $110.00 | +0.7% | +1.7% | +2.3% | +2.5% | +1.8% | +2.4% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $117.21 | $116.65 | -0.5% | -2.4% | -2.7% | -3.3% | -4.9% | -4.2% |
| Mar 5 | BofA Securities | Maintains | Buy → Buy | — | $114.74 | $114.74 | +0.0% | +0.6% | +1.1% | +2.3% | +2.2% | -0.3% |
| Mar 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $114.74 | $114.74 | +0.0% | +0.6% | +1.1% | +2.3% | +2.2% | -0.3% |
| Mar 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $115.99 | $117.25 | +1.1% | -1.1% | -0.5% | +0.0% | +1.2% | +1.1% |
| Feb 18 | Deutsche Bank | Upgrade | Hold → Buy | — | $104.08 | $104.25 | +0.2% | +1.1% | +3.4% | +5.7% | +5.6% | +6.7% |
| Feb 13 | BofA Securities | Maintains | Buy → Buy | — | $103.31 | $104.84 | +1.5% | +2.6% | +0.7% | +1.9% | +4.2% | +6.5% |
| Feb 12 | JP Morgan | Maintains | Overweight → Overweight | — | $96.14 | $101.74 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% |
| Feb 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $96.14 | $101.74 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% |
| Feb 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $96.14 | $101.74 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% |
| Feb 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $96.14 | $101.74 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% |
| Feb 12 | Baird | Maintains | Neutral → Neutral | — | $96.14 | $101.74 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% |
| Feb 12 | Needham | Maintains | Hold → Hold | — | $96.14 | $101.74 | +5.8% | +7.5% | +10.2% | +8.3% | +9.5% | +12.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | O'Day Daniel PatrickDir/Off | Chairman & CEO | Sell | 3,050 | $130.01 | $397K | 632,567 | +1.55% | +5.79% |
| Apr 28, 2026 | O'Day Daniel PatrickDir/Off | Chairman & CEO | Sell | 6,950 | $128.79 | $895K | 635,617 | +1.55% | +5.79% |
8-K · 2.02
!! High
Assembly Biosciences, Inc. -- 8-K 2.02: Earnings Results
Assembly Biosciences reported quarterly earnings results; investors should review the attached press release for specific financial performance metrics and guidance updates affecting the ASMB and GILD stock valuations.
May 7
8-K · 2.02
!! High
Gilead Sciences, Inc. -- 8-K 2.02: Earnings Results
Gilead Sciences reported first-quarter 2026 earnings on May 7, 2026, providing investors with updated financial performance metrics and operational results for the three-month period.
May 7
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.
Apr 30
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences is acquiring Arcellx at $115 per share through a tender offer, providing ACLX shareholders a defined exit while consolidating GILD's cell therapy portfolio.
Apr 28
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K · 8.01
!! High
Arcus Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Gilead's acquisition of Arcus Biosciences faces setback as the STAR-121 trial of domvanalimab and zimberelimab failed to meet futility analysis criteria for first-line lung cancer treatment.
Apr 20
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences' tender offer to acquire Arcellx at $115 per share represents a significant premium and provides shareholders with a clear exit opportunity at a fixed price through April 2026.
Apr 17
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LYEL's new executive Lang receives competitive compensation ($560K base plus 40% bonus potential) with full 2026 bonus eligibility, signaling board confidence in his leadership and commitment to retention during critical strategic execution.
Apr 15
SC TO-T/A
! Medium
Arcellx, Inc. -- Tender Offer Amendment
Gilead Sciences is acquiring Arcellx at $115 per share in cash, valuing the cell therapy company at approximately $2.1 billion.
Apr 1
8-K
Unknown — 8-K Filing
Assembly Biosciences' optimistic 2025 guidance and pivot toward viral disease therapeutics could drive share appreciation if pipeline candidates advance, but investors should verify clinical progress claims against actual trial data.
Mar 19
8-K
Lyell Immunopharma, Inc. -- 8-K Filing
Lyell Immunopharma appointed a new executive officer with participation in the company's severance plan, potentially affecting shareholder equity structure and executive compensation costs.
Mar 9
SC TO-T
!!! Very High
Arcellx, Inc. -- Tender Offer
Gilead Sciences is acquiring Arcellx for $115 per share in cash, representing a significant premium that validates Arcellx's cell therapy platform and expands Gilead's oncology portfolio.
Mar 6
8-K · 8.01
!! High
Citius Oncology, Inc. -- 8-K 8.01: Material Event / Announcement
Citius Oncology announced positive Phase 1 safety and efficacy data for LYMPHIR combined with CD19 CAR-T therapy in relapsed/refractory DLBCL patients, potentially validating a combination treatment approach.
Mar 4
8-K · 5.02
!!! Very High
MBX Biosciences, Inc. -- 8-K 5.02: Executive Change
MBX Biosciences replaced CFO Richard Bartram with interim CFO John Smither, effective March 16, 2026, signaling potential leadership transition during a critical period for the company.
Feb 27
8-K · 1.01
!!! Very High
Gilead Sciences Inc -- 8-K 1.01: Merger Agreement
Gilead Sciences has entered into a merger agreement, signaling potential strategic consolidation that could reshape its portfolio and create shareholder value through the combined entity's operations.
Feb 23
8-K
Arcellx, Inc. -- 8-K Filing
Gilead Sciences' cash acquisition of Arcellx remains on track with no financing risk, as the offer period opens for at least 20 business days with potential extension under merger terms.
Feb 23
8-K
Gilead Sciences Inc -- 8-K Filing
I cannot generate a meaningful analysis from this filing excerpt, as it only contains boilerplate regulatory language about exhibits and incorporation by reference, with no substantive business information about Gilead Sciences.
Feb 10
Data updated apr 25, 2026 11:27am
· Source: massive.com